Actavis plc, of Dublin, received a complete response letter (CRL) from the FDA for its new drug application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension. Data submitted to the FDA in support of approval of this NDA included a single phase III randomized, controlled trial of approximately 4,100 patients.